Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals.
Ethnicity
MASLD
Outcomes
Prevalence
Risk factors
Sex
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
28
03
2024
accepted:
20
06
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
28
6
2024
Statut:
aheadofprint
Résumé
To overcome the limitations of the term "non-alcoholic fatty liver disease" (NAFLD), the term metabolic-associated steatotic liver disease (MASLD) was introduced. While epidemiologic studies have been conducted on MASLD, there is limited evidence on its associated sex and ethnic variations. This study assesses the differences across sex and race-ethnicity on the prevalence, associated risk factors and adverse outcomes in individuals with MASLD. Data retrieved from the National Health and Nutrition Examination Survey between 1999 to 2018 was analyzed. Prevalence, clinical characteristics, and outcomes were evaluated according to sex and race-ethnicity. Adverse outcomes and mortality events were analyzed using multivariate analyses. Of 40,166 individuals included, 37.63% had MASLD. There was a significant increase in MASLD prevalence from 1999 to 2018 among Mexican Americans (Annual Percentage Change [APC] + 1.889%, p < 0.001), other Hispanics (APC + 1.661%, p = 0.013), NH Whites (APC + 1.084%, p = 0.018), NH Blacks (APC + 1.108%, p = 0.007), and females (APC + 0.879%, p = 0.030), but not males. Females with MASLD were at lower risk of all-cause (HR: 0.766, 95%CI 0.711 to 0.825, p < 0.001), cardiovascular disease-related (CVD) (SHR: 0.802, 95% CI 0.698 to 0.922, p = 0.002) and cancer-related mortality (SHR: 0.760, 95% CI 0.662 to 0.873, p < 0.001). Significantly, NH Blacks have the highest risk of all-cause and CVD-related mortality followed by NH Whites then Mexican Americans. There has been an increase in prevalence in most race-ethnicities over time. While the change in definition shows no significant differences in previous associations found in NAFLD, the increased mortality in NH Whites relative to Mexican Americans remains to be explored.
Sections du résumé
BACKGROUND
BACKGROUND
To overcome the limitations of the term "non-alcoholic fatty liver disease" (NAFLD), the term metabolic-associated steatotic liver disease (MASLD) was introduced. While epidemiologic studies have been conducted on MASLD, there is limited evidence on its associated sex and ethnic variations.
AIMS
OBJECTIVE
This study assesses the differences across sex and race-ethnicity on the prevalence, associated risk factors and adverse outcomes in individuals with MASLD.
METHODS
METHODS
Data retrieved from the National Health and Nutrition Examination Survey between 1999 to 2018 was analyzed. Prevalence, clinical characteristics, and outcomes were evaluated according to sex and race-ethnicity. Adverse outcomes and mortality events were analyzed using multivariate analyses.
RESULTS
RESULTS
Of 40,166 individuals included, 37.63% had MASLD. There was a significant increase in MASLD prevalence from 1999 to 2018 among Mexican Americans (Annual Percentage Change [APC] + 1.889%, p < 0.001), other Hispanics (APC + 1.661%, p = 0.013), NH Whites (APC + 1.084%, p = 0.018), NH Blacks (APC + 1.108%, p = 0.007), and females (APC + 0.879%, p = 0.030), but not males. Females with MASLD were at lower risk of all-cause (HR: 0.766, 95%CI 0.711 to 0.825, p < 0.001), cardiovascular disease-related (CVD) (SHR: 0.802, 95% CI 0.698 to 0.922, p = 0.002) and cancer-related mortality (SHR: 0.760, 95% CI 0.662 to 0.873, p < 0.001). Significantly, NH Blacks have the highest risk of all-cause and CVD-related mortality followed by NH Whites then Mexican Americans.
CONCLUSION
CONCLUSIONS
There has been an increase in prevalence in most race-ethnicities over time. While the change in definition shows no significant differences in previous associations found in NAFLD, the increased mortality in NH Whites relative to Mexican Americans remains to be explored.
Identifiants
pubmed: 38940975
doi: 10.1007/s10620-024-08540-4
pii: 10.1007/s10620-024-08540-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–1347.
doi: 10.1097/HEP.0000000000000004
pubmed: 36626630
Ng CH, Lim WH, Chin YH, Yong JN, Zeng RW, Chan KE et al. Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients’ perspectives. Aliment Pharmacol Ther. 2022;56:570–579.
doi: 10.1111/apt.17121
pubmed: 35791632
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;79:E93–E94.
pubmed: 37983810
Song SJ, Che-To Lai J, Lai-Hung Wong G, Wai-Sun Wong V, Cheuk-Fung Yip T. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023;80:e54.
doi: 10.1016/j.jhep.2023.07.021
pubmed: 37541393
Hagstrom H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023;80:e76.
doi: 10.1016/j.jhep.2023.08.026
pubmed: 37678723
Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the united states: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198–210.
doi: 10.1016/j.cgh.2017.09.041
pubmed: 28970148
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465.
doi: 10.1038/ng.257
pubmed: 18820647
pmcid: 2597056
Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R et al. The MBOAT7-TMC4 VARIANT rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150:1219–1230.
doi: 10.1053/j.gastro.2016.01.032
pubmed: 26850495
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457–1469.
doi: 10.1002/hep.30626
pubmed: 30924946
Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565–582.
doi: 10.1016/S0140-6736(20)31561-0
pubmed: 32828189
pmcid: 7440877
CDC. National Health and Nutrition Examination Survey (NHANES). 2017;2020.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
doi: 10.1186/1471-230X-6-33
pubmed: 17081293
pmcid: 1636651
(WHO) WHO. Obesity and Overweight 2021
National Health and Nutrition Examination Survey (NHANES) MEC Laboratory Procedures Manual Centers for disease control and prevention. 2017.
Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41:65–76.
doi: 10.1111/apt.13012
pubmed: 25376360
Organisation WH. Obesity and Overweight Fact Sheet: World Health Organisation; 2021 https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight .
American Diabetes A.2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care 2018;42:S13–S28.
doi: 10.2337/dc19-S002
O’Hearn M, Lauren BN, Wong JB, Kim DD, Mozaffarian D. Trends and disparities in cardiometabolic health among US adults, 1999–2018. J Am Coll Cardiol. 2022;80:138–151.
doi: 10.1016/j.jacc.2022.04.046
pubmed: 35798448
pmcid: 10475326
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:1269–1324.
doi: 10.1161/HYP.0000000000000066
pubmed: 29133354
Cao YT, Xiang LL, Qi F, Zhang YJ, Chen Y, Zhou XQ. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547.
doi: 10.1016/j.eclinm.2022.101547
pubmed: 35844772
pmcid: 9284399
Pennisi G, Enea M, Pandolfo A, Celsa C, Antonucci M, Ciccioli C et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol. 2023;21:1293–1302.
doi: 10.1016/j.cgh.2022.06.013
pubmed: 35842119
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–373.
doi: 10.1016/S2468-1253(19)30383-8
pubmed: 32027858
pmcid: 7066580
Kallwitz ER, Daviglus ML, Allison MA, Emory KT, Zhao L, Kuniholm MH et al. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol. 2015;13:569–576.
doi: 10.1016/j.cgh.2014.08.037
pubmed: 25218670
Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274–283.
doi: 10.4254/wjh.v6.i5.274
pubmed: 24868321
pmcid: 4033285
Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–1894.
doi: 10.1002/hep.24283
pubmed: 21381068
Chinchilla-Lopez P, Ramirez-Perez O, Cruz-Ramon V, Canizales-Quinteros S, Dominguez-Lopez A, Ponciano-Rodriguez G et al. More evidence for the genetic susceptibility of Mexican population to nonalcoholic fatty liver disease through PNPLA3. Ann Hepatol. 2018;17:250–255.
doi: 10.5604/01.3001.0010.8644
pubmed: 29469042
Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 2015;3:78–84.
doi: 10.14218/JCTH.2014.00037
pubmed: 26357637
pmcid: 4542078
Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology. 1999;29:719–727.
doi: 10.1002/hep.510290307
pubmed: 10051473
Besse-Patin A, Leveille M, Oropeza D, Nguyen BN, Prat A, Estall JL. Estrogen signals through peroxisome proliferator-activated receptor-gamma coactivator 1alpha to reduce oxidative damage associated with diet-induced fatty liver disease. Gastroenterology. 2017;152:243–256.
doi: 10.1053/j.gastro.2016.09.017
pubmed: 27658772
Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med. 2020;287:711–722.
doi: 10.1111/joim.13035
pubmed: 32128904
Ochoa-Allemant P, Marrero JA, Serper M. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States. Hepatol Commun. 2023. https://doi.org/10.1097/HC9.0000000000000324 .
doi: 10.1097/HC9.0000000000000324
pubmed: 38051551
pmcid: 10697602
Nguyen VH, Le I, Ha A, Le RH, Rouillard NA, Fong A et al. Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: a longitudinal real-world study. Clin Mol Hepatol. 2023;29:1002–1012.
doi: 10.3350/cmh.2023.0205
pubmed: 37691484
pmcid: 10577349
Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62:352–360.
doi: 10.1016/j.metabol.2012.08.005
pubmed: 22999011
Post WS, Watson KE, Hansen S, Folsom AR, Szklo M, Shea S et al. Racial and ethnic differences in all-cause and cardiovascular disease mortality: The MESA study. Circulation. 2022;146:229–239.
doi: 10.1161/CIRCULATIONAHA.122.059174
pubmed: 35861763
pmcid: 9937428
Weight N, Moledina S, Volgman AS, Bagur R, Wijeysundera HC, Sun LY et al. Socioeconomic disparities in the management and outcomes of acute myocardial infarction. Heart. 2023;110:122–131.
doi: 10.1136/heartjnl-2023-322601
pubmed: 37558395
Peterson K, Anderson J, Boundy E, Ferguson L, McCleery E, Waldrip K. Mortality disparities in racial/ethnic minority groups in the Veterans Health Administration: an evidence review and map. Am J Public Health. 2018;108:e1–e11.
doi: 10.2105/AJPH.2017.304246
pubmed: 29412713
pmcid: 5803811
Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology. 2023;77:1382–1403.
doi: 10.1002/hep.32743
pubmed: 35993341
Bailey ZD, Feldman JM, Bassett MT. How structural racism works—racist policies as a root cause of U.S. racial health inequities. N Engl J Med. 2021;384:768–773.
doi: 10.1056/NEJMms2025396
pubmed: 33326717
Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36:1470–1478.
doi: 10.1111/jgh.15363
pubmed: 33269500
Heidemann C, Schulze MB, Franco OH, van Dam RM, Mantzoros CS, Hu FB. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation. 2008;118:230–237.
doi: 10.1161/CIRCULATIONAHA.108.771881
pubmed: 18574045
pmcid: 2748772
Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in non-alcoholic fatty liver disease. Clin Mol Hepatol. 2022. https://doi.org/10.3350/cmh.2022.0096
doi: 10.3350/cmh.2022.0096
pubmed: 36517002
pmcid: 10029957
Chew NWS, Ng CH, Chan KE, Chee D, Syn N, Nobuharu T, et al. The Fibrosis-4 (FIB-4) Index predicts cardiovascular major adverse events and mortality in patients with non-alcoholic fatty liver disease. Can J Cardiol. 2022. https://doi.org/10.1016/j.cjca.2022.07.016
doi: 10.1016/j.cjca.2022.07.016
pubmed: 36202591